ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

32.20
0.21 0.64
OTC
Prev Close 32.41
Open 32.13
Day Low/High 32.07 / 32.44
52 Wk Low/High 25.25 / 33.77
Volume 1.91M
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 179.91B
Div & Yield N.A. (N.A)

Latest News

Roche Diagnostics Recognizes Sentara Consolidated Laboratories As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Sentara Consolidated Laboratories As Roche Molecular Center Of Excellence

Institution joins strategic network designed to help accelerate advancement of new methods in molecular diagnostics, anatomic pathology and sequencing

Genentech To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis

Genentech To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive MS (PPMS)...

FDA Grants Genentech's TECENTRIQ (Atezolizumab) Accelerated Approval As Initial Treatment For Certain People With Advanced Bladder Cancer

FDA Grants Genentech's TECENTRIQ (Atezolizumab) Accelerated Approval As Initial Treatment For Certain People With Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Lucentis (Ranibizumab Injection) For Diabetic Retinopathy, The Leading Cause Of Blindness Among Working Age Adults In The United States

FDA Approves Genentech's Lucentis (Ranibizumab Injection) For Diabetic Retinopathy, The Leading Cause Of Blindness Among Working Age Adults In The United States

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Announces Positive Interim Results For Emicizumab In Phase III Study Of Children With Hemophilia A

Genentech Announces Positive Interim Results For Emicizumab In Phase III Study Of Children With Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A...

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.

Roche Launches New Global Certified Provider Program For Target Enrichment In Genomic Sequencing

Roche Launches New Global Certified Provider Program For Target Enrichment In Genomic Sequencing

-- Program helps meet customers' needs for both basic and clinical research applications

Phase III Study Shows Genentech's Alecensa® Was Superior To Crizotinib In A Specific Type Of Lung Cancer

Phase III Study Shows Genentech's Alecensa® Was Superior To Crizotinib In A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global, randomized Phase III ALEX study met its primary endpoint and showed that Alecensa ® (alectinib) as an initial...

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.

FDA Advisory Committee Unanimously Recommends Approval Of Genentech's Subcutaneous Rituximab For Certain Blood Cancers

FDA Advisory Committee Unanimously Recommends Approval Of Genentech's Subcutaneous Rituximab For Certain Blood Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA shares tested one-year highs Friday after the Food & Drug Administration approved rare form of skin cancer treatment that could cost patients as much as $13,000 per month.

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears

Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears

Despite all the prior failures and blowups, an Alzheimer's drug study -- no matter how unlikely to succeed -- remains an irresistible lure for some investors.

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Strategic alliance network is designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized healthcare

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Here's Why Weight Watchers' New CEO Should Be a Woman

Here's Why Weight Watchers' New CEO Should Be a Woman

Could Oprah Winfrey herself take the helm at the diet company?

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates.

Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win

Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win

Roche shares surged in Zurich Thursday after the Swiss drugmaker said trials of its key breast cancer drug showed solid results when compared to chemotherapy.

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced positive results...

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's sovereign wealth fund, the world's biggest and a key investor in Apple and Alphabet, earned more than $53 billion last year as equity returns surged.